Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: December 09, 2025
Assessing factor consumption and bleeding outcomes of prophylaxis with 3 commonly prescribed factor IX products for hemophilia B: A retrospective patient medical record analysis in the United States.
Journal: Journal of managed care & specialty pharmacy
Published: November 14, 2025
Bleeding Complications, Transfusion, and Acute Care Costs After Major Arthroplasty in Patients With Hereditary Bleeding Disorders: A National Healthcare Database Analysis.
Journal: Anesthesia and analgesia
Published: April 04, 2025
Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
Journal: Drugs in R&D
Published: October 25, 2024
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
Journal: Drugs in R&D
Published: July 18, 2024
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
Journal: The New England journal of medicine
Published: July 17, 2024
Outcomes of a Vial-Sparing Antithrombin III Protocol in Pediatric Extracorporeal Membrane Oxygenation.
Journal: ASAIO journal (American Society for Artificial Internal Organs : 1992)
Published: October 19, 2023
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.
Journal: Acta haematologica
Published: September 21, 2023
Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: January 06, 2023
Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
Journal: Current medical research and opinion
Published: April 07, 2022
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
Journal: Thrombosis and haemostasis
Published: December 09, 2020
Last Updated: 09/26/2026